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BK virus is associated with hemorrhagic cystitis after hematopoietic stem cell transplantation (HSCT),
although evidence supporting a causal relationship remains limited. Although BK viruria is common after
HSCT, BK viremia may better predict clinically signiﬁcant cystitis, similar to its predictive value for
nephropathy after kidney transplantation. We hypothesized that BK viremia would precede hemorrhagic
cystitis in a cohort of 88 consecutive children prospectively enrolled to originally study thrombotic micro-
angiopathy in the ﬁrst 100 days after allogeneic HSCT. Cox regression models with time-varying covariates
assessed the association between different BK viremia cutoffs and the development of hemorrhagic cystitis,
deﬁned as at least macroscopic hematuria. Subjects with a peak plasma BK viral load 1 to 9999 copies/mL had
an adjusted hazard ratio of 4.2 (95% conﬁdence interval (CI), 1.3 to 13.7) for the development of hemorrhagic
cystitis. Those with peak BK viremia >100,000 copies/mL had an adjusted hazard ratio of 116.8 (95% CI, 12 to
1136) for cystitis. Other independent risk factors for hemorrhagic cystitis included age >7 years and HHV-6
viremia. Neither graft-versus-host disease nor achieving engraftment increased the risk for cystitis. If ther-
apeutic strategies are found to be effective, these observations may support screening for BK viremia after
HSCT, as currently recommended for other DNA viruses.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION transplantation [13]. Kidney transplantation guidelines
Hemorrhagic cystitis is a signiﬁcant complication after
hematopoietic stem cell transplantation (HSCT) and is asso-
ciated with prolonged hospitalization, urinary tract
obstruction, and possibly death [1-4]. Early-onset cystitis,
occurring within 72 hours of conditioning, is typically related
to chemotherapy [5,6]. With the use of mesna and aggressive
hydration, late-onset cystitis (>72 hours after conditioning)
has become the more common post-transplantation bladder
complication [3,7,8]. Potential risk factors for late-onset
cystitis include the type of conditioning chemotherapy,
timing of engraftment, development of graft-versus-host
disease (GVHD), presence of BK virus infection in the blood
or urine, and other viral infections [3,7,9].
BK virus identiﬁed in the urine (viruria) is common after
HSCT and occurs even in the absence of hemorrhagic cystitis
[10]. Up to 80% of HSCT recipients are noted to have BK
viruria [2,4], but only 10% to 25% of all patients develop
clinically signiﬁcant cystitis [3,8,11,12]. The mechanism by
which BK virus infection leads to hemorrhagic cystitis in
a subset of transplantation patients is unknown, but may be
related to immune-mediated bladder injury, GVHD, or later
effects of conditioning chemotherapy, such as cyclophos-
phamide [3,8,9].
BK viremia (10,000 copies/mL) is more speciﬁc than
viruria for predicting nephropathy after kidneydgments on page 1181.
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13.05.002recommend BK testing of plasma, not urine, as the most
effective screening approach [14]. Studies in adults have
assessed if BK viremia also predicts hemorrhagic cystitis after
HSCT, with conﬂicting results [15-17]. We previously
reported that peak BK viremia, but not viruria, in the ﬁrst
year after HSCT was associated with higher-grade cystitis in
a retrospective study of 21 children [18]. To increase the
causal evidence for an association between infection and
disease, we hypothesized that BK viremia would precede
cystitis in an independent, prospective cohort of children
undergoing HSCT.MATERIALS AND METHODS
Study Population
We analyzed a previously completed prospective cohort of 100
consecutive children who received HSCT at Cincinnati Children’s Hospital
Medical Center from September 2010 to December 2011. This cohort was
originally developed to study thrombotic microangiopathy (TMA) in the ﬁrst
100 days after transplantation. We included subjects who consented to have
their information used for any scientiﬁc purpose (98 of 100 subjects), and
the research was approved by the institutional review boards at Cincinnati
Children’s Hospital Medical Center and The Children’s Hospital of Phila-
delphia. We further restricted our analyses to the 88 allogeneic recipients to
decrease the heterogeneity of the study population.Outcome Deﬁnition
Cases of hemorrhagic cystitis were ﬁrst identiﬁed by reviewing
discharge summaries. Additionally, as part of the original protocol to study
TMA, subjects had routine urinalyses performed weekly while admitted. To
supplement case ascertainment, we reviewed nursing assessments and
daily progress notes for subjects with 50 red blood cells (RBC) per high-
power ﬁeld on these protocol urinalyses. Each subject’s maximum grade
of hemorrhagic cystitis was deﬁned according to the criteria of Bedi et al. [8],Transplantation.
Table 1
Characteristics of the Study Cohort
Hemorrhagic
Cystitis (n ¼ 17)
Controls
(n ¼ 71)
P
Value*
Age, yr, median (IQR) 10.2 (7.8 to 14.0) 5.7 (1.8 to 15.2) .04
Male 11 (64.7) 45 (63.4) 1.00
Diagnosis group .07
Malignancy 4 (23.5) 20 (28.2)
Immunodeﬁciency 5 (29.4) 31 (43.7)
Bone marrow failure 5 (29.4) 19 (26.8)
Genetic/metabolic 2 (11.8) 1 (1.4)
Benign hematologic 1 (5.9) 0 (0)
Donor cell source .77
Unrelated 13 (76.5) 50 (70.4)
Related 4 (23.5) 21 (29.6)
Donor cell product .50
Marrow 12 (70.6) 56 (78.9)
Peripheral blood 2 (11.8) 9 (12.7)
Cord blood 3 (17.7) 6 (8.4)
Conditioning therapy .11
Myeloablative 12 (70.6) 34 (47.9)
Reduced Intensity 5 (29.4) 37 (52.1)
Conditioning agents
received (yes
versus no)
Testicular radiation 1 (5.9) 3 (4.2) 1.00
Total body irradiation 2 (11.85) 10 (14.1) 1.00
Busulfan 9 (52.9) 23 (32.4) .16
Cyclophosphamide 12 (70.6) 34 (47.9) .11
Antithymocyte globulin 11 (64.7) 23 (32.4) .02
Fludarabine 7 (41.2) 44 (62.0) .17
Melphalan 5 (29.4) 38 (53.5) .10
Alemtuzumab 5 (29.4) 34 (47.9) .19
Data presented as n (%) unless otherwise indicated. Bold typeface indicates
statistical signiﬁcance.
* Categorical variables with Fisher exact test; continuous variables with
Mann-Whitney U.
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hematuria; grade 3, the presence of clots; and grade 4, urinary tract
obstruction. We deﬁned hemorrhagic cystitis as grade 2 to identify the
most clinically signiﬁcant cases, consistent with prior reports [8,15].
Subjects could be diagnosed with hemorrhagic cystitis only once, deﬁned as
the ﬁrst date recorded in the medical record.
BK Virus PCR Testing
New onset BK viremia was the primary, time-varying risk factor. Assays
for BK viremia were performed as clinically indicated (primarily for unex-
plained microscopic hematuria on urinalysis, gross hematuria, and/or an
elevation in serum creatinine) or using stored plasma at predeﬁned intervals
over the course of follow-up. Plasma specimens were stored (80 C) at
baseline before conditioning, weekly while admitted, when TMA was
diagnosed, and at day 100. To approximate BK viremia from day 0 until day
100, stored samples were tested so that each subject had at least 3 plasma
BK virus PCR results, with at least 1 measured between days 0 to 14,15 to 85,
and 100  14 days after HSCT.
Because viral replication is often evaluated on a logarithmic scale, we
assessed BK viremia at the following cutoff values before the development of
hemorrhagic cystitis: (1) 0; (2) 1 to 9999 copies/mL; (3) 10,000 to 99,999
copies/mL; and (4)  100,000 PCR plasma copies/mL. Subjects were placed
into 1 of these 4 threshold categories based on their peak plasma PCR result
before thedevelopmentof hemorrhagic cystitis or their peakvalueduring the
ﬁrst 100 days (in those without cystitis). For subjects with 1 identical peak
value, the ﬁrst datewas used in the analysis. In this cohort, clinical testing for
BK viruriawas performed in HSCT recipientswith hematuria or symptoms of
cystitis; a systematic assessment for BK viruria was not performed.
BK virus testing for clinical indications and on stored specimens were
both performed in the Cincinnati Children’s Hospital Medical Center
Molecular Pathology Laboratory. Viral DNA was extracted from plasma
samples on the Roche MagNA Pure 96 System (Basel, Switzerland) using the
Total Nucleic Acid Kit (Grand Island, New York). The input sample volume
was 200 mL and the ﬁnal volume was 100 mL of DNA eluate. A real-time PCR
reaction (Applied Biosystems 7500 FAST System) used primers targeting the
VP3 gene for BK virus with a sequence-speciﬁc TaqMan hydrolysis probe
labeled with FAM reporter molecules on the 50 end and TAMRA quencher
molecules on the 30 end [19]. The reaction used 23 mL of enzyme/oligonu-
cleotide master mix with 5 mL of DNA template for patient samples, as well
as positive and negative controls. A quantiﬁed standard material obtained
from Advanced Biotechnologies, Inc. (Columbia, Maryland) was serially
diluted, and the known concentrations of the dilutions were programmed
into the instrument software to allow for quantiﬁcation of the patient
samples, which were then compared to the standard curve. The ﬁnal viral
concentrations were determined using a calculation accounting for the
amount of sample used for DNA extraction, DNA eluate obtained from the
extraction, and DNA eluate used in the reaction. All of the PCR assays were
run with a separate housekeeping control to exclude the presence of any
inhibitors. For analysis purposes, values less than the limit of detection (ie,
<500 copies/mL) were converted by dividing by the square root of 2 [20].
Covariates
We prospectively captured demographic information and trans-
plantation data starting 3 weeks before conditioning until day 114 (day
100 þ 2 weeks). Age was analyzed both as a continuous variable and as
a dichotomous variable at a cutoff above and below the median age of the
cohort (7 years). To test current theories on risk factors for hemorrhagic
cystitis, the development of GVHD and the timing of engraftment were
analyzed as time-varying covariates assessed before the development of
hemorrhagic cystitis. Engraftment was analyzed separately as the ﬁrst day
when (1) the absolute neutrophil count was>500/mL for 3 consecutive days,
(2) the platelet count was >20,000/mL for 7 days without transfusion, or (3)
the platelet count was >50,000/mL for 7 days without transfusion. Each
subject’s absolute lymphocyte count was examined on the day of peak
viremia, the day of peak viruria, and the day hemorrhagic cystitis was
diagnosed. Transplantation complications were deﬁned using clinical
criteria consistent with published guidelines for GVHD [21], sinusoidal
obstruction syndrome [22], and TMA [23,24]. As part of routine clinical care,
plasma PCR testing for Epstein-Barr virus (EBV), cytomegalovirus (CMV),
and adenovirus was performed at least weekly during the ﬁrst 100 days.
Testing for HHV-6 viremia was ordered at the discretion of the treating
physician, but was typically performed for unexplained fever. Infection with
these viruses was considered to be present the ﬁrst day a plasma PCR was
>0 copies/mL.
Statistical Analysis
Descriptive statistics were reported as medians, interquartile ranges
(IQR), and frequencies. Differences in categorical and continuous variableswere assessed with the Fisher exact and Wilcoxon rank sum tests, respec-
tively. We used a time-to-event analysis with Cox regression models to
calculate hazard ratios (HR) and their associated 95% conﬁdence intervals
(CI) for the outcome of hemorrhagic cystitis, censoring at time of death or
the end of the follow-up period at day 114, whichever came ﬁrst. Time-
dependent variables, before the development of hemorrhagic cystitis,
were initially evaluated in univariate models and included BK viremia at the
different threshold levels, GVHD, TMA, engraftment, EBV, CMV, adenovirus,
and HHV-6 viremia. Any variable (time-dependent or not) with a univariate
P value <.2 was considered for inclusion in the multivariate analyses. Study
data were collected using REDCap (Research Electronic Data Capture, Van-
derbilt University, Nashville, Tennessee) hosted at Cincinnati Children’s
Hospital Medical Center [25]. Statistical analyses were performed using
STATA statistical software (version 12, College Station, Texas).
RESULTS
Hemorrhagic Cystitis Identiﬁcation
A total of 1438 urinalyses were performed on the 88
allogeneic recipients during the ﬁrst 100 days. Seventeen of
88 subjects (19%) developed grade 2 hemorrhagic cystitis
based on review of these urinalyses and the clinical record.
The median time to diagnosis of cystitis was dayþ25 (IQR, 18
to 42 days). Grade 2 cystitis was diagnosed in 7 of 17 (41%),
grade 3 in 9 of 17 (53%), and grade 4 in 1 of 17 (6%). An
additional 12 of 88 subjects (14%) had at least 1 urinalysis
with 50 RBC per high-power ﬁeld and/or symptoms of
dysuria without gross hematuria, and were therefore clas-
siﬁed as <grade 2 cystitis and not included in our case
deﬁnition.
Based on clinical indication, testing for BK viruria was
performed in 41 of 88 (47%) allogeneic recipients: 14 who
developed grade 2 cystitis and 27 who did not. Among
these 27 subjects without grade 2 cystitis, 18 of 27 (67%)
had at least 1 positive urine PCR (>0 copies/mL) during the
ﬁrst 100 days. Among the 14 subjects with grade 2 cystitis
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(>0 copies/mL) anytime during the ﬁrst 100 days, with 9 of
13 (69%) positive before the diagnosis of cystitis.
Cohort Characteristics
The pretransplantation characteristics of the cohort are
shown in Table 1. By univariate analyses, subjects with
hemorrhagic cystitis were signiﬁcantly older and more likely
to have received antithymocyte globulin conditioning.
Underlying diagnosis, type of preparatory regimen, and
speciﬁc conditioning agents (ie, antithymocyte globulin)were
strongly correlated, making it difﬁcult to assess the indepen-
dent association of these variables with hemorrhagic cystitis.
The post-transplantation characteristics of the cohort are
shown in Table 2. Subjects with hemorrhagic cystitis were
more likely to develop adenoviremia at any time during the
ﬁrst 100 days and receive more platelet transfusions.
Although both groups had low absolute lymphocyte counts
at the time of peak viremia and peak viruria, there was no
difference in these values between the groups. In the
subjects with cystitis, 9 of 17 (53%) received cidofovir. Cido-
fovir was prescribed for persistent BK viremia after the date
of hemorrhagic cystitis in 6 of 9 subjects and before cystitis
for adenoviremia in 3 of 9. There was no signiﬁcant differ-
ence between the groups in GVHD prophylaxis (Table 2).
Only 2 children (both in the noncystitis group) received
prophylaxis with tacrolimus or sirolimus. There was no
signiﬁcant difference between the groups in the maximum
grade of acute GVHD, sinusoidal obstruction syndrome (2 ofTable 2
Post-transplantation Characteristics of the Study Cohort in the First 100 Days
Hemorrhagic Cystitis (
GVHD prophylaxis
Cyclosporine 17 (100)
Antithymocyte globulin 2 (11.8)
Methylprednisolone 9 (52.9)
Methotrexate 5 (29.4)
Mycophenolate mofetil 1 (5.9)
Engraftment, median (IQR)
Neutrophil dayþ 12 (10 to 21)
Platelet 20,000/mL dayþ 26 (19 to 38)
Platelet 50,000/mL dayþ 31 (26.5 to 53.5)
ALC at peak viremia (K/mcL) 100 (60 to 150)
ALC at peak viruria (K/mcL) 395 (100 to 580)
ALC at cystitis (K/mcL) 200 (100 to 580)
Antimicrobials
Ciproﬂoxacin 13 (76.5)
Levoﬂoxacin 0 (0)
Cidofovir 9 (52.9)
GVHD 7 (41.2)
Thrombotic microangiopathy 10 (58.8)
Dialysis 1 (5.9)
Platelet transfusions, median (IQR) 14 (12 to 17)
Red cell transfusions, median (IQR) 4 (2 to 7)
BK viremia, median (IQR) Before cystitis
Number of plasma tests 2 (2 to 4)
Peak copies/mL 884 (0 to 1653)
Peak viremia threshold groups
0 copies/mL 6 (35)
1 to 9999 copies/mL 9 (53)
10,000 to 99,999 copies/mL 0 (0)
100,000 copies/mL 2 (12)
Other DNA viremia Anytime in the ﬁrst 10
Adenovirus 9 (52.9)
CMV 4 (23.5)
EBV 7 (41.2)
HHV-6 5 (29.4)
GVHD indicates graft-versus-host disease; ALC, absolute lymphocyte count; CMV,
Data are presented as n (%), unless otherwise indicated. Bold typeface indicates st
* Categorical variables with Fisher exact test; continuous variables with Mann-W71, 3% in control group, 0 of 17 in cystitis group), or the need
for dialysis. Fluoroquinolones and intravenous immuno-
globulin have been reported as having potential activity
against BK virus [26-30]. There was no difference in ﬂuo-
roquinolone use between the groups and all patients
received intravenous immunoglobulin to maintain the IgG
level in the normal range for their age. No subject had his or
her immunosuppression reduced based on the diagnosis of
hemorrhagic cystitis. The median follow-up time for the
entire cohort was 122 days (IQR, 85.5 to 128 days).
Plasma BK PCR Results
The 88 allogeneic recipients underwent a total of 883
plasma BK virus PCR tests (summarized in Table 2). The
median time from the peak plasma PCR to the diagnosis of
cystitis was 11.5 days (IQR, 9 to 14 days) in the 2 subjects with
a peak >100,000 copies/mL and 4 days (IQR, 3 to 13 days) in
the 9 subjects with a peak plasma PCR 1 to 9999 copies/mL.
The signiﬁcance of this difference is unknown given the 2
subjects with a peak plasma PCR 100,000 copies/mL before
hemorrhagic cystitis had plasma testing initially performed
foracuteelevations in serumcreatinine. Bothof these children
had a 2-log increase in their plasma PCR in the 2 to 3 months
before the onset of cystitis. No other subject with cystitis had
a log increase in his or her BK plasma PCR before symptoms.
Univariate Analysis of Time-Varying Exposures
Subjects without BK viremiawere not at increased risk for
hemorrhagic cystitis, whereas those with a peak plasma PCRn ¼ 17) Controls (n ¼ 71) P Value*
65 (91.65) .59
5 (7.0) .62
44 (62.0) .58
18 (25.3) .76
9 (12.7) .68
12 (10 to 20) .40
25 (18 to 36) .62
28 (19 to 43) .18
120 (40 to 380) .29
150 (40 to 340) .20
d d
45 (63.4) .40
3 (4.2) 1.00
12 (16.9) <.01
23 (32.4) .57
27 (38.0) .17
6 (8.4) 1.00
11 (4 to 17) .02
4 (2 to 6) .34
In the ﬁrst 100 days
3 (3 to 12) <.01
354 (0 to 2424) .54
35 (49) .42
27 (38) .28
5 (7) .58
4 (6) .33
0 days
18 (25.3) .04
18 (25.3) 1.00
17 (23.9) .22
10 (14.1) .16
cytomegalovirus; EBV, Epstein-Barr virus.
atistical signiﬁcance.
hitney U.
Table 3
Univariate Analyses Assessing the Association of Time-Varying Exposures
with Subsequent Hemorrhagic Cystitis
Variable Hazard Ratio
(95% Conﬁdence
Interval)
P
Value
Primary Exposures
Peak BK plasma PCR*
0 copies/mL 0.9 (.3 to 2.5) .83
1 to 9999 copies/mL 5.3 (2.0 to 14.6) <.01
10,000 to 99,999 copies/mL No cystitis subject met
this criterion
‡100,000 copies/mL 34.3 (4.6 to 256.1) <.01
Secondary Exposures
Graft-versus-host disease 1.0 (.2 to 4.9) .99
Thrombotic microangiopathy 2.2 (.7 to 6.9) .18
Neutrophil engraftment .6 (.1 to 2.7) .49
Platelet engraftment >20,000/mL .4 (.1 to 1.3) .12
Platelet engraftment >50,000/mL .3 (.1 to 1.4) .14
Adenoviremia >0 copies/mL 1.3 (.4 to 4.7) .70
CMV viremia >0 copies/mL 1.6 (.4 to 5.8) .48
EBV viremia >0 copies/mL 2.1 (.6 to 7.8) .26
HHV-6 viremia >0 copies/mL 7.6 (2.6 to 22.2) <.01
CMV indicates cytomegalovirus; EBV, Epstein-Barr virus.
Bold type face indicates statistically signiﬁcant.
* Peak BK plasma PCR before cystitis in the hemorrhagic cystitis group
and anytime during the ﬁrst 100 days in the noncystitis group. For subjects
withmore than 1 identical peak value, the ﬁrst date was used in the analysis.
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a signiﬁcantly higher risk of later cystitis (Table 3). We could
not assess the cutoff level of 10,000 to 99,999 copies/mL
because no cystitis subject had a peak PCR meeting this
threshold before cystitis. Therewas no signiﬁcant association
between GVHD and the development of subsequent
hemorrhagic cystitis. Point estimates suggested that
achieving platelet engraftment was associated with a lower
risk of cystitis at both a platelet count of >20,000/mL and
a platelet count >50,000/mL, although not statistically
signiﬁcant. Subjects with HHV-6 viremia were signiﬁcantly
more likely to develop hemorrhagic cystitis with a HR of
7.6 (95% CI, 2.6 to 22.2). Figure 1 illustrates the timing of BKFigure 1. Timing of covariates in relation to the diagnosis of hemorrhagic cystitis. For
hemorrhagic cystitis. The dotted vertical line shows the median time to the diagnos
viremia and HHV-6 viremia occurred before cystitis was diagnosed. The median time
cystitis was diagnosed.viremia, HHV-6 viremia, GVHD, platelet engraftment, and BK
viruria in the 17 subjects with hemorrhagic cystitis.Multivariate Analysis
After adjusting for age, HHV-6 viremia, achieving platelet
engraftment, EBV viremia, antithymocyte globulin, cyclo-
phosphamide, and busulfan, BK viremia at cutoff levels of 1
to 9999 copies/mL and 100,000 copies/mL were indepen-
dently associated with later hemorrhagic cystitis (Table 4).
Age >7 years and HHV-6 viremia were also independently
associated with hemorrhagic cystitis. Neither conditioning
with busulfan or cyclophosphamide, the type of conditioning
(myeloablative versus reduced intensity) received, or the
development of TMAwere signiﬁcantly associated with later
hemorrhagic cystitis after adjustment (data not shown).DISCUSSION
We observed that BK viremia independently predicted
the development of hemorrhagic cystitis in children who
received allogeneic HSCT. Analyzing BK viremia as a time-
varying exposure, children with increasing peak plasma
PCRs had a higher risk for cystitis in the ﬁrst 100 days after
transplantation. Neither GVHD nor achieving engraftment,
when also considered as time-varying covariates, were
associated with an increased risk of hemorrhagic cystitis. In
the multivariate model, older patient age and HHV-6 viremia
were also associated with cystitis.
Several adult reports have examined the association
between BK viremia and hemorrhagic cystitis after HSCT,
with conﬂicting results. Leung et al. [17] prospectively
identiﬁed 6 of 50 (12%) patients who developed grade 2
cystitis after engraftment. The level of viremia did not predict
hemorrhagic cystitis, although formal testing for temporal
associations was not performed. Erard et al. [16] reported BK
viremia was associated with postengraftment hemorrhagic
cystitis (n ¼ 3) in 132 consecutive adults in a univariate,
time-dependent analysis. Later, the same group used a case-
control design to retrospectively examine 30 allogeneiceach variable, box plots summarize data from the 17 subjects diagnosed with
is of cystitis after stem cell infusion (day þ25). The median time to peak BK
to GVHD, platelet engraftment >50,000/mL, and peak BK viruria occurred after
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B.L. Laskin et al. / Biol Blood Marrow Transplant 19 (2013) 1175e1182 1179recipients with grade 2 cystitis identiﬁed over a 24-year
period [15]. Cases had BK virus plasma testing within
3 weeks before or during hemorrhagic cystitis and were
matched to 81 controls on age. BK viremia >10,000 copies/
mL had a sensitivity of 63% and a speciﬁcity of 95% for
diagnosing hemorrhagic cystitis. Finally, Wong et al. [31]
randomly selected 20 patients for BK virus plasma testing
from a prospective cohort of 140 adults. BK viremia remained
low (100 copies/mL) in the ﬁrst 2 months after HSCT,
precluding assessment of the relationship between viremia
and clinical outcomes.
The conﬂicting associations between BK viremia and
clinical disease reported in the literature may, in part, result
because each institution uses its own PCR assay and BK virus
exists as at least 4 distinct genotypes. Without standardized
procedures, these technical issues regarding BK virus testing
make comparisons across studies difﬁcult. Along these lines,
a recent case report of a kidney transplantation recipient
demonstrated variable PCR results that depended on which
laboratory analyzed the specimens [32].
To our knowledge, this is the largest study to analyze
temporal associations between BK viremia and subsequent
hemorrhagic cystitis in children after HSCT. Cesaro et al. [4]
prospectively observed that 4 of 15 (27%) children who
received allogeneic transplantation developed grade 2
cystitis, and viremia >1000 copies/mL (which preceded
cystitis by a median of 17 days) had a sensitivity of 40% and
speciﬁcity of 93% for the detection of hemorrhagic cystitis.
Others have evaluated the association between BK viremia
and hemorrhagic cystitis, but not their timing. Gorcyznska
et al. [2] prospectively examined 102 children and found 10
of 102 (10%) had at least 1 positive qualitative PCR for BK
viremia, with 8 of 10 who developed cystitis. Similar to
our ﬁndings, hemorrhagic cystitis was less common in those
<5 years of age, and there was no association between GVHD
or total body irradiation and cystitis. Gaziev et al. [1]
prospectively followed children who underwent HSCT for
hemoglobinopathies from baseline until day 100. Of
64 patients, 34 tested had BK viremia on at least 1 specimen
and 18 of 64 (28%) on at least 2 samples. Independent risk
factors for hemorrhagic cystitis were antithymocyte globulin,
peak BK viruria >100,000, and acute GVHD, but not BK
viremia. Finally, our preliminary retrospective assessment
in 21 children with BK viremia found that a peak plasma PCR
>10,000 copies/mL in the ﬁrst transplantation year was
associated with higher-grade cystitis, but we did not assess
the timing of infection in relation to symptoms [18].
Children may have a different risk for BK viruserelated
disease compared with adults [33]. Older age was a signiﬁ-
cant risk factor for hemorrhagic cystitis in our patient pop-
ulation, as shown by others [2]. In fact, the median age of our
subjects with hemorrhagic cystitis was 10 years, consistent
with data from the general population, in which the BK
seroprevalence rate reportedly reachs 90% by about 10 years
of age [34]. Although only speculation, this ﬁnding supports
the hypothesis that BK virus infection after HSCT is
secondary to latent viral reactivation rather than primary
infection [10]. In a study of 140 adult HSCT recipients, higher
pretransplantation BK virus IgG titers, a possible marker of
latent infection, were associated with subsequent peaking
of urine BK virus, but the authors were unable to assess
its relationship with clinical disease because of their
small sample size [31]. In contrast, a recent study in 50
children who underwent allogeneic HSCT found that 5 of 6
subjects with hemorrhagic cystitis were seronegative before
B.L. Laskin et al. / Biol Blood Marrow Transplant 19 (2013) 1175e11821180transplantation [10]. Seroconversion after transplantation
was associated with decreasing BK viremia and clinical
improvement in the patients with cystitis.
The exact mechanism of bladder injury from BK virus
after HSCT remains unknown. Leung et al. [9] proposed that
conditioning chemotherapy ﬁrst damages the bladder. The
combination of decreased viral-speciﬁc immunity from
chemotherapy and GVHD prophylaxis allows BK virus to
reactivate, which becomes apparent as increasing BK viruria.
Finally, donor immune cells attack the bladder epithelium,
leading to hemorrhagic cystitis. This “immune reconstitu-
tion” phenomenon is reported to occur after engraftment in
the presence of GVHD [1,3,7,31]. However, hemorrhagic
cystitis is not always associated with GVHD [2,15,17,35], and
others have refuted this conceptual model given that
hemorrhagic cystitis occurs during periods of lymphopenia
[15]. Additionally, high-dose corticosteroids, which would
presumably attenuate an immune reconstitution response,
have also been associated with an increased risk of hemor-
rhagic cystitis and BK viremia [16].
We did not ﬁnd that GVHD or achieving engraftment
increased the risk for hemorrhagic cystitis in our time-
varying analyses. Myeloablative conditioning and/or the
use of cyclophosphamide or busulfan were also not associ-
ated with hemorrhagic cystitis, in contrast to prior reports
[15,35]. Antithymocyte globulin was associated with cystitis
in our univariate analyses, possibly supporting the role of
signiﬁcant immunosuppression and decreased virus-speciﬁc
T cells in the pathogenesis of disease. Because patients often
received combinations of these conditioning therapies, it
was not possible to determine the risk associated with
individual agents in the multivariate analyses. Nevertheless,
we speculate that latent BK virus reactivation occurs in the
absence of virus-speciﬁc T cells that normally prevent viral
replication, leading to subclinical bladder cell lysis and
detectable viremia before the onset of overt cystitis [10].
Although we did not observe a difference in absolute
lymphocyte counts between the groups, the role of BK-
speciﬁc T cells in the pathogenesis of BK virus-associated
genitourinary disease is supported by preliminary studies
after HSCT and kidney transplantation and deserves further
study [10,36-38].
The potential role of virus-speciﬁc immunity is also
strengthenedbyourﬁnding thatHHV-6 viremiapredicted the
development of hemorrhagic cystitis. EBV, CMV, adenovirus,
andHHV-6, similar toBKvirus, are alsoDNAviruses frequently
contributing to disease in transplantation recipients. Adeno-
virus and CMV are less commonly associated with hemor-
rhagic cystitis, alone or in combinationwith BK virus [3,9,39].
Wang et al. reported that HHV-6 viremia (HHV-6B variant)
may be associated with hemorrhagic cystitis in 72 allogeneic
recipients (HR, 2.6; CI,1.0 to 7.0; P¼ .06), but did not assess for
BK virus infection in their patients [40]. One case report also
describes an association between HHV-6 viremia and
hemorrhagic cystitis [41]. We observed that 6 of 17 of our
subjects with hemorrhagic cystitis did not have BK viremia of
anydegreebefore symptoms, suggestingeither thatBKvirus is
not the sole cause of bladder injury or that we missed the
window of detection in these subjects. The role of HHV-6
infection after HSCT is still being deﬁned, but typically
involves central nervous system disease [42]. The strong
association between HHV-6 viremia, BK viremia, and hemor-
rhagic cystitis we observedmay point to a novel viral cause of
bladder injury or simply reﬂect the degree of immunosup-
pression after HSCT. Interestingly, HHV-6 reportedlydecreases human leukocyte antigen class I expression in an
effort to evade cytotoxic T cell attack, potentially increasing
the susceptibility to other infections [42-44].
The strengths of our analysis include the prospective
enrollment of consecutive HSCT recipients combined with
the prospective collection of samples and clinical data. This
allowed for the rigorous assessment of multiple potential
covariates using time-dependent survival methods. Past
studies using only dichotomous characterization of dynamic
variables (ie, GVHD and engraftment) may have led to biased
inferences. Finally, the inclusion of children permitted
adjustment for age in a patient population that may have
a different seroprevalence of infection compared with adults
[10,34].
Although we leveraged data from a completed prospec-
tive cohort, the cases of hemorrhagic cystitis were identiﬁed
by reviewing themedical record.We believe the likelihood of
signiﬁcant misclassiﬁcation bias was low because the review
of nursing note assessments and physician progress notes
was supplemented by urinalysis results collected prospec-
tively on all participants at weekly intervals while admitted.
It is possible that ascertainment bias resulted from more
frequent plasma PCR testing in sicker patients, especially
because plasma BK testing was typically ordered in those
with microscopic hematuria. However, when we analyzed
only PCR results that occurred before hemorrhagic cystitis,
we actually found that patients with cystitis had less
frequent BK plasma testing. Finally, we did not have sufﬁ-
cient urine PCR results to test the association between viruria
and hemorrhagic cystitis. Prior studies that examined BK
viruria and hemorrhagic cystitis after HSCT have reported
that a 3-log increase in BK viruria over baseline was asso-
ciated with the development of cystitis [17,29,31]. Future
research is needed to systematically measure viruria,
viremia, and outcomes in all subjects and in a larger study
population.
After kidney transplantation, BK viremia >10,000
copies/mL is highly predictive of biopsy-proven nephropathy
[13]. Similar to HSCT, BK viruria is likely nonspeciﬁc after
kidney transplantation [45]. Therefore, current consensus
kidney transplantation guidelines recommend BK plasma
PCR screening monthly for the ﬁrst 3 to 6 months, then every
3 months until the ﬁrst year after kidney transplantation
[14]. Similar guidelines are currently not available in the
HSCT population because the optimal frequency of BK
plasma testing is not known [42]. It is possible that monthly
screening after HSCT is not sufﬁcient and that, similar to CMV
and EBV, at least weekly screening is required in the imme-
diate post-transplantation period in children.
Retrospective studies in HSCT recipients suggest that BK
viremia >10,000 copies/mL may also be associated with
hemorrhagic cystitis [15,18]. Although we were unable to
demonstrate that this 10,000 copy/mL cutoff was associated
with disease, we did observe that even higher BK plasma
viral loads independently predicted subsequent cystitis. It
also remains unknown why hemorrhagic cystitis is more
common after HSCT compared with after kidney trans-
plantation. Hemorrhagic cystitis may result from a more
profound decrease in virus-speciﬁc T cells, supported by our
observations that concomitant viremia (HHV-6), delayed
engraftment, and T celledepleting therapy were potentially
associated with cystitis.
In the ﬁrst 100 days after HSCT, severe infections affect up
to 15% of patients [46], and infection remains a common
cause of death in allogeneic recipients [42]. Decreasing the
B.L. Laskin et al. / Biol Blood Marrow Transplant 19 (2013) 1175e1182 1181burden of viral disease would hopefully improve outcomes
after HSCT. The strong association between BK viremia and
clinically signiﬁcant hemorrhagic cystitis justiﬁes the
prospective assessment of prophylactic and treatment
strategies [3]. Causal evidence would be strengthened if
treating or preventing BK viremia resulted in a lower risk of
hemorrhagic cystitis [9]. Preliminary reports have suggested
that ﬂuoroquinolone prophylaxis (because of its anti-
topoisomerase activity) reduces BK viruria, but not hemor-
rhagic cystitis, after HSCT and BK viremia after kidney
transplantation [27-29]. In children receiving kidney trans-
plantations, early reduction of immunosuppression after the
detection of BK viremia has also prevented BK virus
nephropathy [47]. If these or other strategies are shown to be
effective in HSCT recipients, it may support frequent plasma
monitoring for BK virus, as currently recommended for other
DNA viruses such as CMV and adenovirus [42]. Finally,
further research is needed to determine if HHV-6 viremia
causes hemorrhagic cystitis or if our observed effect simply
reﬂects an overall degree of immunosuppression.ACKNOWLEDGMENTS
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